February 06, 2017 14:00 ET
TORONTO, ONTARIO--(Marketwired - Feb. 6, 2017) - Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.
Date: Effective immediately, February 6, 2017
Canadian Securities Exchange (CSE)Listings(416) 367-7340Listings@thecse.comwww.thecse.com
See all RSS Newsfeeds